Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues
Anna Porwit
(1)
,
Marie Béné
(2)
,
Carolien Duetz
(3)
,
Sergio Matarraz
(4, 5, 6)
,
Uta Oelschlaegel
(7)
,
Theresia Westers
(3)
,
Orianne Wagner-Ballon
(8, 9)
,
Shahram Kordasti
(10)
,
Peter Valent
(11)
,
Frank Preijers
(12)
,
Canan Alhan
(3)
,
Frauke Bellos
(13)
,
Peter Bettelheim
(14)
,
Kate Burbury
(15, 16)
,
Nicolas Chapuis
(17, 18)
,
Eline Cremers
(19)
,
Matteo Della Porta
(20, 21)
,
Alan Dunlop
(22)
,
Lisa Eidenschink-Brodersen
(23)
,
Patricia Font
(24)
,
Michaela Fontenay
(18, 17)
,
Willemijn Hobo
(11)
,
Robin Ireland
(25)
,
Ulrika Johansson
(25)
,
Michael Loken
(23)
,
Kiyoyuki Ogata
(26)
,
Alberto Orfao
(5, 6, 4)
,
Katherina Psarra
(27)
,
Leonie Saft
(28)
,
Dolores Subira
(29)
,
Jeroen Te Marvelde
(30)
,
Denise Wells
(23)
,
Vincent van der Velden
(30)
,
Wolfgang Kern
(13)
,
Arjan van de Loosdrecht
(3)
1
Skane University Hospital [Lund]
2 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
3 Amsterdam UMC - Amsterdam University Medical Centers
4 Universidad de Salamanca [España] = University of Salamanca [Spain]
5 IBSAL - Instituto de Investigación Biomédica de Salamanca
6 CIBERONC - Centro de Investigación Biomédica en Red de Cáncer
7 University Hospital Carl Gustav Carus [Dresden, Germany]
8 Hôpital Henri Mondor
9 IMRB - Institut Mondor de Recherche Biomédicale
10 King‘s College London
11 Medizinische Universität Wien = Medical University of Vienna
12 Radboud University Medical Center [Nijmegen]
13 MLL Munich Leukemia Laboratory
14 Ordensklinikum Linz Elisabethinen
15 University of Melbourne
16 Peter MacCallum Cancer Centre
17 Hôpital Cochin [AP-HP]
18 IC UM3 (UMR 8104 / U1016) - Institut Cochin
19 MUMC - Maastricht University Medical Centre
20 IRCCS Milan - Istituto Clinico Humanitas [Milan]
21 Hunimed - Humanitas University [Milan]
22 The Royal Marsden NHS Foundation Trust [London]
23 HematoLogics, Inc. [Seattle, WA, USA]
24 Hospital General Universitario "Gregorio Marañón" [Madrid]
25 University Hospitals Bristol
26 MRTC Japan - Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan]
27 Evangelismos Athens General Hospital
28 Karolinska University Hospital [Stockholm]
29 Hospital Universitario de Guadalajara
30 Erasmus MC - Erasmus University Medical Center [Rotterdam]
2 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
3 Amsterdam UMC - Amsterdam University Medical Centers
4 Universidad de Salamanca [España] = University of Salamanca [Spain]
5 IBSAL - Instituto de Investigación Biomédica de Salamanca
6 CIBERONC - Centro de Investigación Biomédica en Red de Cáncer
7 University Hospital Carl Gustav Carus [Dresden, Germany]
8 Hôpital Henri Mondor
9 IMRB - Institut Mondor de Recherche Biomédicale
10 King‘s College London
11 Medizinische Universität Wien = Medical University of Vienna
12 Radboud University Medical Center [Nijmegen]
13 MLL Munich Leukemia Laboratory
14 Ordensklinikum Linz Elisabethinen
15 University of Melbourne
16 Peter MacCallum Cancer Centre
17 Hôpital Cochin [AP-HP]
18 IC UM3 (UMR 8104 / U1016) - Institut Cochin
19 MUMC - Maastricht University Medical Centre
20 IRCCS Milan - Istituto Clinico Humanitas [Milan]
21 Hunimed - Humanitas University [Milan]
22 The Royal Marsden NHS Foundation Trust [London]
23 HematoLogics, Inc. [Seattle, WA, USA]
24 Hospital General Universitario "Gregorio Marañón" [Madrid]
25 University Hospitals Bristol
26 MRTC Japan - Metropolitan Research and Treatment Centre for Blood Disorders [Tokyo, Japan]
27 Evangelismos Athens General Hospital
28 Karolinska University Hospital [Stockholm]
29 Hospital Universitario de Guadalajara
30 Erasmus MC - Erasmus University Medical Center [Rotterdam]
Anna Porwit
- Fonction : Auteur
- PersonId : 762163
- ORCID : 0000-0003-0709-2713
Marie Béné
- Fonction : Auteur
- PersonId : 767851
- ORCID : 0000-0002-6569-7414
Orianne Wagner-Ballon
- Fonction : Auteur
- PersonId : 756203
- ORCID : 0000-0001-9071-6683
- IdRef : 079569668
Nicolas Chapuis
- Fonction : Auteur
- PersonId : 768515
- ORCID : 0000-0003-0601-3948
- IdRef : 12957189X
Matteo Della Porta
- Fonction : Auteur
Dolores Subira
- Fonction : Auteur
- PersonId : 762164
- ORCID : 0000-0002-9485-0529
Vincent van der Velden
- Fonction : Auteur
- PersonId : 821107
- ORCID : 0000-0001-9457-3763
Résumé
Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow‐up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN i MDS Flow) on the analytical issues in MFC for the diagnostic work‐up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34 + CD19 − ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work‐up. Looking forward, several machine‐learning‐based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine‐learning‐based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.